Atsena Reports LIGHTHOUSE data at ARVO - Scorecard - MDSpire

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min

Share

Clinical Scorecard: Atsena Reports LIGHTHOUSE data at ARVO

At a Glance

CategoryDetail
ConditionX-linked retinoschisis (XLRS)
Key MechanismsGene therapy using ATSN-201 with AAV.SPR capsid for targeted gene expression in photoreceptors.
Target PopulationMale patients ages 6 and older with XLRS caused by RS1 gene mutations.
Care SettingClinical trial setting, specifically a phase 1/2 study.

Key Highlights

  • ATSN-201 shows good safety and efficacy signs in Part A of the LIGHTHOUSE study.
  • No serious adverse events related to treatment reported; most adverse events were Grade 1-2.
  • Enrollment for Part B is ongoing, evaluating additional adult and pediatric patients.

Guideline-Based Recommendations

Diagnosis

  • Clinical diagnosis of XLRS based on RS1 gene mutations.

Management

  • Subretinal injection of ATSN-201 in a dose-escalation and dose-expansion trial.

Monitoring & Follow-up

  • Assessment of safety and efficacy through microperimetry, visual acuity, and macular structure.

Risks

  • Surgical risks related to the procedure; no dose-limiting toxicities observed.

Patient & Prescribing Data

Adult and pediatric patients with XLRS.

ATSN-201 was well tolerated with no treatment-related serious adverse events.

Clinical Best Practices

  • Monitor patients for adverse events related to the surgical procedure.
  • Evaluate preliminary data from adult cohort before dosing pediatric patients.

References

Original Source(s)

Atsena Reports LIGHTHOUSE data at ARVO

  • May 1, 2025

Related Content

Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

Vascular Alterations in the Choroid of Eyes Affected by Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy: Fresh Perspectives

Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid resolution may help identify patients with nAMD who can maintain longer faricimab dosing intervals.